A Phase 2 interventional study of Emraclidine and Placebo in Schizophrenia, sponsored by AbbVie. Recruiting at 7 sites in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-15.
Sponsored by AbbVie · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 27 studies in Schizophrenia by AbbVie — 1 open to participants now, 1 under way, none of them phase 3. Schizophrenia · AbbVie.
Among the 27 studies in Schizophrenia by AbbVie, this one is the 13th largest by planned enrollment, is the only one that started in 2025, is one of 13 in phase 2, and was the 27th registered.
3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →1 of the 27 studies in Schizophrenia by AbbVie is open now, in 1 country.
By country, each count listing its studies:
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
27 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 268 is above the median of 70 across 2,951 interventional studies indexed under Schizophrenia.
Median enrollment 268 across the 27 interventional studies. Of the 26 that completed or were terminated, 11 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.
Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 27 studies in Schizophrenia by AbbVie, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Schizophrenia is a common and severe psychiatric illness characterized by extreme disturbances of cognition and thought, affecting language, perception and sense of self. This study will assess adverse events, change in disease activity, and how oral emraclidine moves through the body in adult participants with schizophrenia
Emraclidine is an investigational drug being developed for the treatment of schizophrenia. Participants are placed in one of two parts, Part A or Part B, where each group will receive a different treatment. Participants will receive either oral emraclidine or placebo. Approximately 268 participants will be enrolled across roughly 32 sites in the United States.
Participants in Part A will be assigned to oral emraclidine or placebo administered for 14 days or up to 21 days depending on cohort. Cohorts without titration include a 14-day treatment period at target dose. Cohorts with titration are comprised of a titration period of up to 7 days and a 14-day treatment period at the cohort target dose. Participants in Part B will receive oral emraclidine or placebo. Participants will be followed for 30 days after the last dose of the study drug.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DSM diagnostic criteria
The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will be assigned to receive one of multiple ascending doses of oral emraclidine for 14 or up to 21 days, followed by a 30-day safety follow-up period.
Drug: Emraclidine
Participants will be assigned to receive one of multiple ascending doses of oral placebo for 14 or up to 21 days, followed by a 30-day safety follow-up period.
Drug: Placebo
Participants will receive oral emraclidine for 42 days followed by a 30-day safety follow-up period.
Drug: Emraclidine
Participants will receive placebo for 42 days followed by a 30-day safety follow-up period.
Drug: Placebo
Oral Tablets
Oral Tablets
Number of Participants with Adverse Events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study.
Time frame: Up to approximately 74 days
Part A Only-Maximum Observed Plasma Concentration (Cmax) of Emraclidine
Cmax of Emraclidine
Time frame: Up to approximately 24 days
Part A Only-Time to Cmax (Tmax) of Emraclidine
Tmax of Emraclidine
Time frame: Up to approximately 24 days
Part A Only-Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) of Emraclidine
AUCt of Emraclidine
Time frame: Up to approximately 24 days
Part A Only-Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Emraclidine
AUCtau of Emraclidine
Time frame: Up to approximately 24 days
Part A Only- Minimum plasma concentration (Cmin) of Emraclidine
Cmin of Emraclidine
Time frame: Up to approximately 21 days
Part A Only-Average plasma concentration (Cavg) of Emraclidine
Cavg of Emraclidine
Time frame: Up to approximately 21 days
Part A Only- Terminal Phase Elimination Half-Life (t1/2) of Emraclidine
Terminal phase elimination half-life of Emraclidine
Time frame: Up to approximately 21 days
Part A Only-Terminal elimination rate constant (λz) of Emraclidine
λz of Emraclidine
Time frame: Up to approximately 21 days
Part A Only-Apparent Clearance of Drug from Plasma (CL/F) of Emraclidine
CL/F of Emraclidine
Time frame: Up to approximately 21 days
Part A Only-Apparent Volume of Distribution DuringTerminal Phase (Vz/F) of Emraclidine
Vz/F of Emraclidine
Time frame: Up to approximately 21 days
Part A Only-Peak-to-trough ratio (PTR) of Emraclidine
PTR of Emraclidine
Time frame: Up to approximately 21 days
Part A Only- Accumulation ratio for Cmax (RacCmax) of Emraclidine
RacCmax of Emraclidine
Time frame: Up to approximately 21 days
Part A Only-Accumulation ratio for AUCtau (RacAUCtau) of Emraclidine
RacAUCtau of Emraclidine
Time frame: Up to approximately 21 days
Part A Only-Maximum Observed Plasma Concentration (Cmax) of Metabolite (CV-0000364)
Cmax of Metabolite (CV-0000364)
Time frame: Up to approximately 24 days
Part A Only-Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Metabolite (CV-000036)
AUCtau of Metabolite (CV-000036)
Time frame: Up to approximately 24 days
Part A Only-Time to Cmax (Tmax) of Metabolite (CV-0000364)
Tmax of Metabolite (CV-0000364)
Time frame: Up to approximately 24 days
Part A Only-Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) Metabolite (CV-000036)
AUCt of Metabolite (CV-000036)
Time frame: Up to approximately 24 days
Part A Only-Metabolite to Parent Ratio (MRCmax) of Metabolite (CV-0000364) calculated from Cmax
MRCmax of Metabolite (CV-000036)
Time frame: Up to approximately 21 days
Part A Only- Metabolite to Parent Ratio (MRAUCtau) of Metabolite (CV-0000364)
MRAUCtau of Metabolite (CV-0000364)
Time frame: Up to approximately 21 days
Part A Only- Terminal Phase Elimination Half-Life (t1/2) of of Metabolite (CV-0000364)
Terminal phase elimination half-life of Metabolite (CV-0000364)
Time frame: Up to approximately 21 days
Part A Only-Terminal elimination rate constant (λz) of Metabolite (CV-0000364)
λz of Metabolite (CV-0000364)
Time frame: Up to approximately 21 days
Part A Only-Peak-to-trough ratio (PTR) of Metabolite (CV-0000364)
PTR of Metabolite (CV-0000364)
Time frame: Up to approximately 21 days
Part B Only-Change from Baseline in Positive and Negative Syndrome Scale (PANSS) total score
PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Time frame: Up to approximately week 6
Part B Only-Maximum Observed Plasma Concentration (Cmax) of Emraclidine
Cmax of Emraclidine
Time frame: Up to approximately 24 days
Part B Only-Time to Cmax (Tmax) of Emraclidine
Tmax of Emraclidine
Time frame: Up to approximately 24 days
Part B Only-Area Under the Concentration-Time Curve from Time 0 to Time t (AUCt) of Emraclidine
AUCt of Emraclidine
Time frame: Up to approximately 24 days
Part B Only-Area under the plasma concentration-time curve over the dosing interval (AUCtau) of Emraclidine
AUCtau of Emraclidine
Time frame: Up to approximately 24 days
Part B Only-Change from Baseline in in Clinical Global Impression of Severity (CGIS) score
CGIS is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from "normal, to at all ill" (1) to "among the most extremely ill patients" (5), with higher scores indicating greater anxiety severity.
Time frame: Up to approximately Week 6
Part B Only-Change from Baseline in Positive and Negative Syndrome Scale (PANSS) total score
PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Time frame: Up to approximately 74 days
Part B Only-Change from Baseline in in Clinical Global Impression of Severity (CGIS) score
CGIS is a single, clinician-reported item that measures the clinician's impression of a participant's current anxiety severity considering their total clinical experience with the patient population. The measure uses a 7-point Likert rating scale with responses ranging from "normal, to at all ill" (1) to "among the most extremely ill patients" (5), with higher scores indicating greater anxiety severity.
Time frame: Up to approximately 53 days
Part B Only-Number of Participants achieving ≥ 30% improvement in PANSS total score
PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Time frame: Up to approximately week 6
Part B Only-Number of Participants achieving remission (PANSS total score ≤ 60)
PANSS is a 30-item clinician-reported rating scale which assesses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS consists of 3 subscales containing a total of 30 symptom constructs. For each symptom construct, severity is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.
Time frame: Up to approximately week 6
Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Supporting information: Study protocol, Statistical analysis plan
Time frame: For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Data sharing details ↗ · vivli.org
No publications or documents are linked to this record.
Started Aug 2025 (actual). Primary completion is estimated for Feb 2028, 30 months after the start.
Of 57 industry-sponsored phase 2 interventional studies under Schizophrenia, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 32. This study's planned 30 months is above that.
Counting every sponsor, half of 101 studies reached it within 25 months; a quarter within 15 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Emraclidine